EKSO experienced a dramatic revenue decline alongside severe cash depletion, signaling acute financial distress for the medical device company.
The company's revenue fell by nearly half while cash reserves plummeted from $6.5M to just $1.2M, creating immediate liquidity concerns. Combined with widening operating losses and the removal of business development language, this suggests EKSO is facing fundamental challenges in its exoskeleton rehabilitation device business that could threaten operational continuity.
EKSO's financial position deteriorated significantly across multiple metrics, with revenue declining substantially while operating losses widened from $10.5M to $13.3M. The company's cash position fell dramatically by 82% to just $1.2M, while total assets contracted by nearly 25%. The only modest positive was a reduction in R&D expenses and total liabilities, but these likely reflect cost-cutting measures rather than operational improvements, painting an overall picture of a company in financial distress.
Interest expense surged 93.6% — significant debt increase or rising rates materially impacting earnings.
Cash declined 82% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Revenue declined 48.3% — significant demand weakness or market share loss warrants investigation.
Equity decreased 29% — buybacks or losses reducing book value, monitor solvency ratios.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Current assets declined 25.4% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 24.5% — asset sales, write-downs, or balance sheet optimization underway.
R&D spending cut 21.8% — could signal cost discipline or concerning reduction in innovation investment.
Liabilities reduced 20.5% — deleveraging improves balance sheet strength and financial flexibility.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →